Brief: Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable By FDA’S Approval Of A Telomerase Inhibitor Agent Therapy
07/06/2024 17:35
June 7 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY'S TELOMERE TARGETING FUNCTIONALITY IS
SHOWN
VIABLE BY FDA’S APPROVAL OF A TELOMERASE INHIBITOR AGENT THERAPY
Source text for Eikon: ID:nBw5jHv6Na
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale